Identifying the symptom and functional domains in patients with fibromyalgia: Results of a cross-sectional Internet-based survey in Italy

Journal of Pain Research

Volumn 9, Issue , 2016, Pages 279-286

  Salaffi, Fausto ^a   Mozzani, Flavio ^b   Draghessi, Antonella ^a   Atzeni, Fabiola ^c   Catellani, Rosita ^b   Ciapetti, Alessandro ^d   Di Carlo, Marco ^a   Sarzi Puttini, Piercarlo ^e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Cluster analysis; FAS; Fibromyalgia; FIQR; Internet; Pain; SAPS

Indexed keywords

ADULT; ANXIETY; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE DURATION; ENERGY; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FUNCTIONAL STATUS; HUMAN; INTERNET; ITALY; MAJOR CLINICAL STUDY; MALE; NECK PAIN; PAIN ASSESSMENT; RIGIDITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SLEEP QUALITY; SYMPTOM;

EID: 84974698152     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S100829     Document Type: Article

References (44)

1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;32(Suppl):S6-S21.
2. Salaffi F, De Angelis R, Grassi W; MArche Pain Prevalence, INvestigation Group (MAPPING) study. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23(6):819-828.
3. Wolfe F, Brähler E, Hinz A, Häuser W. Fybromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013;65(5):777-785.
4. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952-960.
5. Ambrose KR, Gracely RH, Glass JM. Fibromyalgia dyscognition: concepts and issues. Reumatismo. 2012;64(4):206-215.
6. Bennett RM, Russell J, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord. 2010;11:134.
7. Hurtig IM, Raak RI, Kendall SA, Gerdle B, Wahren LK. Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain. 2011;17(4):316-322.
8. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916-2922.
9. Hamilton NA, Karoly P, Zautra AJ. Health goal cognition and adjustment in women with fibromyalgia. J Behav Med. 2005;28(5):455-466.
10. Borg C, Padovan C, Thomas-Antérion C, et al. Pain-related mood influences pain perception differently in fibromyalgia and multiple sclerosis. J Pain Res. 2014;7:81-87.
11. Thieme K, Turk DC. Heterogeneity of psychophysiological stress responses in fibromyalgia syndrome patients. Arthritis Res Ther. 2006;8(1):R9.
12. Malin K, Littlejohn GO. Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. J Pain Res. 2012;5:463-471.
13. de Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatol Int. 2008;29(5):509-515.
14. Häuser W, Akritidou I, Felde E, et al. Steps towards a symptom-based diagnosis of fibromyalgia syndrome. Symptom profiles of patients from different clinical settings. Z Rheumatol. 2008;67(6):511-515.
15. Vincent A, Hoskin TL, Whipple MO, et al. OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis. Arthritis Res Ther. 2014;16(5):463.
16. Aldenderfer MS, Blashfield RK. Cluster Analysis. Newbury Park, CA: Sage Publications, Inc; 1984.
17. Salaffi F, Sarzi-Puttini P, Girolimetti R, Atzeni F, Gasparini S, Grassi W. Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clin Exp Rheumatol. 2009;27(Suppl 56):S67-S74.
18. Choy EH, Arnold LM, Clauw DJ, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36(10):2330-2334.
19. Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120.
20. Salaffi F, Franchignoni F, Giordano A, Ciapetti A, Sarzi-Puttini P, Ottonello M. Psychometric characteristics of the Italian version of the revised Fibromyalgia Impact Questionnaire using classical test theory and Rasch analysis. Clin Exp Rheumatol. 2013;31(Suppl 79):S41-S49.
21. Dellifraine JL, Dansky KH. Home-based telehealth: a review and meta-analysis. J Telemed Telecare. 2008;14(2):62-66.
22. Meystre S. The current state of telemonitoring: a comment on the literature. Telemed J E Health. 2005;11(1):63-69.
23. Paré G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base. J Am Med Inform Assoc. 2007;14(3):269-277.
24. Roine R, Ohinmaa A, Hailey D. Assessing telemedicine: a systematic review of the literature. CMAJ. 2001;165(6):765-771.
25. Demiris G, Afrin LB, Speedie S, et al. Patient-centered applications: use of information technology to promote disease management and wellness. A white paper by the AMIA knowledge in motion working group. J Am Med Inform Assoc. 2008;15(1):8-13.
26. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced management of fibromyalgia: a randomized controlled trial. Pain. 2010;151(3):694-702.
27. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-610.
28. Salaffi F, Sarzi-Puttini P, Girolimetti R, Gasparini S, Atzeni F, Grassi W. Development and validation of the self-administered fibromyalgia assessment status: a disease-specific composite measure for evaluating treatment effect. Arthritis Res Ther. 2009;11(4):R125.
29. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol. 1991;18(5):728-733.
30. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36(6):1304-1311.
31. Streiner DL, Norman GR. Methods of administration. In: Health Measurement Scales: A Practical Guide to Their Development and Use. 2nd ed. New York: Oxford Medical; 1995:189-205.
32. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
33. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm. 2012;18(6):415-426.
34. Perrot S, Schaefer C, Knight T, Hufstader M, Chandran AB, Zlateva G. Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains. BMC Musculoskelet Disord. 2012;13:22.
35. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.
36. Wilson HD, Robinson JP, Turk DC. Toward the identification of symptom patterns in people with fibromyalgia. Arthritis Rheum. 2009;61(4):527-534.
37. Docampo E, Collado A, Escaramìs G, et al. Cluster analysis of clinical data identifies fibromyalgia subgroups. PLoS One. 2013;8(9):e74873.
38. Kuner R. Central mechanisms of pathological pain. Nat Med. 2010;16(11):1258-1266.
39. Slobodin G, Reyhan I, Avshovich N, et al. Recently diagnosed axial spondyloarthritis: gender differences and factors related to delay in diagnosis. Clin Rheumatol. 2011;30(8):1075-1080.
40. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol. 2011;93(3):385-404.
41. Williams DA, Clauw DJ, Glass JM. Perceived cognitive dysfunction in fibromyalgia syndrome. J Musculoskelet Pain. 2011;19(2):66-75.
42. Sommer C, Hauser W, Alten R, et al. [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. Schmerz. 2012;26(3):297-310.
43. Peng X, Robinson RL, Mease P, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain. 2015;31(1):7-13.
44. Miró E, Lupiáñez J, Hita E, Martínez MP, Sánchez AI, Buela-Casal G. Attentional deficits in fibromyalgia and its relationships with pain, emotional distress and sleep dysfunction complaints. Psychol Health. 2011;26(6):765-780.